Randomized phase II trial comparing carboplatin plus irinotecan with carboplatin plus amrubicine for extensive disease small-cell lung cancer
Not Applicable
- Conditions
- Small-cell lung cancer
- Registration Number
- JPRN-UMIN000008970
- Lead Sponsor
- orth-Japan lung cancer group
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 70
Inclusion Criteria
Not provided
Exclusion Criteria
1. Severe co-morbidities 2. Symptomatic brain metastasis 3. Not appropriate for clinical trial decided by the attending physician
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Objective response rate
- Secondary Outcome Measures
Name Time Method